C4 Therapeutics (CCCC) Interest & Investment Income (2020 - 2026)

C4 Therapeutics has reported Interest & Investment Income for 7 years, with the latest figure at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income fell 6.54% year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $10.2 million (down 24.23% YoY), and the FY2025 full-year result was $10.3 million, down 28.28% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $2.7 million, down from $2.8 million in the prior quarter.
• The five-year high for Interest & Investment Income was $3.9 million in Q1 2024, with the low at $276000.0 in Q1 2022.
• Average Interest & Investment Income over 5 years is $2.4 million, with a median of $2.6 million recorded in 2023.
• Year-over-year, Interest & Investment Income soared 1156.62% in 2022 and sank 37.23% in 2025.
• Tracing CCCC's Interest & Investment Income over 5 years: stood at $1.7 million in 2022, then surged by 72.62% to $2.9 million in 2023, then rose by 10.75% to $3.3 million in 2024, then declined by 14.91% to $2.8 million in 2025, then retreated by 4.46% to $2.7 million in 2026.
• The last three Interest & Investment Income figures came in at $2.7 million (Q1 2026), $2.8 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.

Peer Comparison